• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Oxidized Lipoprotein Levels: A Case Report.

作者信息

Kotani Kazuhiko, Sakane Naoki

机构信息

Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Division of Community and Family Medicine, Jichi Medical University, Shimotsuke, Japan.

出版信息

J Appl Lab Med. 2020 Sep 1;5(5):1124-1126. doi: 10.1093/jalm/jfaa052.

DOI:10.1093/jalm/jfaa052
PMID:32674159
Abstract
摘要

相似文献

1
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Oxidized Lipoprotein Levels: A Case Report.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂对氧化型脂蛋白水平的影响：一例报告
J Appl Lab Med. 2020 Sep 1;5(5):1124-1126. doi: 10.1093/jalm/jfaa052.
2
Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism.解析并理解前蛋白转化酶枯草杆菌蛋白酶/克新蛋白酶9型抑制剂对载脂蛋白B代谢的影响
Circulation. 2017 Jan 24;135(4):363-365. doi: 10.1161/CIRCULATIONAHA.116.025897.
3
Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels: Another Piece of the Puzzle.前蛋白转化酶枯草溶菌素9型（PCSK9）血浆水平的遗传调控：谜题的又一块拼图。
Circ Genom Precis Med. 2018 May;11(5):e002165. doi: 10.1161/CIRCGEN.118.002165.
4
Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.关于德卡瓦略等人的评论。前蛋白转化酶枯草杆菌蛋白酶/克新9型（PCSK9）抑制剂与2型糖尿病发病：一项超过96000人年的系统评价和荟萃分析。《糖尿病护理》2018年；41：364 - 367。
Diabetes Care. 2018 Apr;41(4):e69. doi: 10.2337/dc17-2563.
5
Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.家族性高胆固醇血症患者的前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9 血清水平表明，前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9 通过 LDL 受体非依赖途径从血浆中清除。
Transl Res. 2012 Aug;160(2):125-30. doi: 10.1016/j.trsl.2012.01.010. Epub 2012 Jan 31.
6
Proprotein convertase subtilisin/kexin type 9 inhibitors on the horns of a dilemma: which lipoprotein we should primarily target - low-density lipoprotein or lipoprotein(a)?前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂面临两难困境：我们应主要针对哪种脂蛋白——低密度脂蛋白还是脂蛋白(a)？
J Cardiovasc Med (Hagerstown). 2022 Sep 1;23(9):635-636. doi: 10.2459/JCM.0000000000001313.
7
[Gene mutations of proprotein convertase subtilisin/kexin type 9 and low density lipoprotein-cholesterol].[前蛋白转化酶枯草溶菌素/kexin 9型基因突变与低密度脂蛋白胆固醇]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 May 24;45(5):444-446. doi: 10.3760/cma.j.issn.0253-3758.2017.05.018.
8
Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.对关于德卡瓦略等人的评论的回应。前蛋白转化酶枯草杆菌蛋白酶/克新9型（PCSK9）抑制剂与2型糖尿病发病：一项超过96000人年的系统评价和荟萃分析。《糖尿病护理》2018年；41:364 - 367。
Diabetes Care. 2018 Apr;41(4):e70-e71. doi: 10.2337/dci17-0069.
9
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke: PheWAS, TreWAS, and More.前蛋白转化酶枯草溶菌素/克新9（PCSK9）状态与缺血性中风的预防：全表型组关联研究、全转录组关联研究及其他
Circ Genom Precis Med. 2018 Jul;11(7):e002247. doi: 10.1161/CIRCGEN.118.002247.
10
Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial).使用前蛋白转化酶枯草溶菌素9单克隆抗体疗法治疗动脉粥样硬化性心血管疾病患者后的残余风险（来自PCSK9抑制对高风险受试者心血管结局的进一步研究试验）
Am J Cardiol. 2017 Oct 1;120(7):1220-1222. doi: 10.1016/j.amjcard.2017.06.063. Epub 2017 Jul 17.

引用本文的文献

1
LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.家族性高胆固醇血症患者的 LDL-胆固醇和 PCSK9：降脂治疗下 PCSK9 变异体的影响。
J Clin Lab Anal. 2021 Nov;35(11):e24056. doi: 10.1002/jcla.24056. Epub 2021 Oct 15.
2
Lipoprotein(a) and Familial Hypercholesterolemia: A Short Review Including the Laboratory Viewpoint.脂蛋白(a)与家族性高胆固醇血症：简短综述，包括实验室视角
Cardiol Res. 2020 Dec;11(6):356-359. doi: 10.14740/cr1145. Epub 2020 Nov 2.